JP2021512059A5 - - Google Patents
Info
- Publication number
- JP2021512059A5 JP2021512059A5 JP2020540265A JP2020540265A JP2021512059A5 JP 2021512059 A5 JP2021512059 A5 JP 2021512059A5 JP 2020540265 A JP2020540265 A JP 2020540265A JP 2020540265 A JP2020540265 A JP 2020540265A JP 2021512059 A5 JP2021512059 A5 JP 2021512059A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- formula
- haloalkyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623387P | 2018-01-29 | 2018-01-29 | |
| US62/623,387 | 2018-01-29 | ||
| US201862674946P | 2018-05-22 | 2018-05-22 | |
| US62/674,946 | 2018-05-22 | ||
| PCT/US2019/015505 WO2019148150A1 (en) | 2018-01-29 | 2019-01-29 | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512059A JP2021512059A (ja) | 2021-05-13 |
| JP2021512059A5 true JP2021512059A5 (enExample) | 2022-02-07 |
Family
ID=67395727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540265A Ceased JP2021512059A (ja) | 2018-01-29 | 2019-01-29 | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11712458B2 (enExample) |
| EP (1) | EP3746426A4 (enExample) |
| JP (1) | JP2021512059A (enExample) |
| AU (1) | AU2019210748B2 (enExample) |
| CA (1) | CA3085457C (enExample) |
| WO (1) | WO2019148150A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111741959B (zh) | 2018-02-19 | 2023-09-05 | 广州麓鹏制药有限公司 | Btk的抑制剂及其突变体 |
| EP3867242A1 (en) | 2018-10-15 | 2021-08-25 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3924350A1 (en) | 2019-02-13 | 2021-12-22 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| US12637467B2 (en) | 2019-02-25 | 2026-05-26 | Newave Pharmaceutical Inc. | Inhibitor of BTK and mutants thereof |
| CN113490669B (zh) * | 2019-03-02 | 2022-12-30 | 上海美志医药科技有限公司 | 一类具有降解Btk活性的化合物 |
| WO2020252397A1 (en) * | 2019-06-12 | 2020-12-17 | Baylor College Of Medicine | Small molecule proteolysis-targeting chimeras and methods of use thereof |
| WO2021018018A1 (en) * | 2019-07-26 | 2021-02-04 | Beigene, Ltd. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use |
| CN110845500B (zh) * | 2019-10-09 | 2021-05-11 | 清华大学 | 靶向btk降解化合物在治疗自身免疫系统疾病中的应用 |
| CN110724143B (zh) * | 2019-10-09 | 2021-03-23 | 清华大学 | 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用 |
| WO2021091575A1 (en) * | 2019-11-08 | 2021-05-14 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| CN112812100B (zh) * | 2019-11-18 | 2022-04-05 | 四川海思科制药有限公司 | 一种具有降解btk激酶的化合物及其制备方法和药学上的应用 |
| CA3160713A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| CN114478532A (zh) | 2020-10-26 | 2022-05-13 | 上海美志医药科技有限公司 | 靶向降解Btk的化合物及其抗肿瘤用途 |
| CN117897388A (zh) * | 2020-12-20 | 2024-04-16 | 广州麓鹏制药有限公司 | Btk蛋白降解剂 |
| US20240058457A1 (en) * | 2020-12-20 | 2024-02-22 | Newave Pharmaceutical Inc. | Btk degrader |
| JP2024505342A (ja) * | 2020-12-23 | 2024-02-06 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | メタクリルアミド系タンパク質結合剤及びその使用 |
| US20240246977A1 (en) * | 2020-12-31 | 2024-07-25 | Beigene Switzerland Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use |
| EP4304655A1 (en) * | 2021-03-12 | 2024-01-17 | Novartis AG | Fatty acid-bifunctional degrader conjugates and their methods of use |
| US20240024490A1 (en) * | 2021-04-09 | 2024-01-25 | The Broad Institute, Inc. | Bifunctional molecules for selective modification of target substrates |
| MX2023012981A (es) * | 2021-05-03 | 2024-01-11 | Nurix Therapeutics Inc | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. |
| CN115304606B (zh) * | 2021-06-21 | 2024-04-19 | 清华大学 | 一种同时靶向btk和gspt1蛋白的降解剂 |
| MX2024004899A (es) | 2021-10-26 | 2024-05-24 | Nurix Therapeutics Inc | Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk. |
| CN118414336A (zh) * | 2021-12-30 | 2024-07-30 | 百济神州有限公司 | 通过使布鲁顿酪氨酸激酶(btk)抑制剂与e3连接酶配体缀合来降解btk及使用方法 |
| CA3240051A1 (en) | 2021-12-30 | 2023-07-06 | Beigene Switzerland Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| JP7805983B2 (ja) | 2022-03-22 | 2026-01-26 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| WO2023227080A1 (zh) * | 2022-05-25 | 2023-11-30 | 百极弘烨(南通)医药科技有限公司 | 一种protac化合物、含其的药物组合物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| US9717745B2 (en) * | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016174183A1 (en) | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| WO2017185036A1 (en) | 2016-04-22 | 2017-10-26 | Dana Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
| EP3484455A2 (en) * | 2016-07-15 | 2019-05-22 | Novartis AG | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| US10842878B2 (en) * | 2016-11-22 | 2020-11-24 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| CA3042294A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| CN109422752B (zh) * | 2017-09-03 | 2023-04-07 | 上海美志医药科技有限公司 | 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物 |
-
2019
- 2019-01-29 JP JP2020540265A patent/JP2021512059A/ja not_active Ceased
- 2019-01-29 CA CA3085457A patent/CA3085457C/en active Active
- 2019-01-29 EP EP19744319.5A patent/EP3746426A4/en not_active Withdrawn
- 2019-01-29 WO PCT/US2019/015505 patent/WO2019148150A1/en not_active Ceased
- 2019-01-29 AU AU2019210748A patent/AU2019210748B2/en not_active Ceased
- 2019-01-29 US US16/963,993 patent/US11712458B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535744A5 (enExample) | ||
| JP2019535746A5 (enExample) | ||
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2022547952A5 (enExample) | ||
| JP2022533398A5 (enExample) | ||
| JP2023529701A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2022501430A5 (enExample) | ||
| JP2021519783A5 (enExample) | ||
| JP2021523221A5 (enExample) | ||
| JP2021522166A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| CN115605479A (zh) | 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2016526540A5 (enExample) | ||
| JP2022505645A5 (enExample) | ||
| JP2014524441A5 (enExample) | ||
| JP2013509431A5 (enExample) | ||
| IL276575B1 (en) | Inhibitors of btk and mutants thereof | |
| JP2005514420A5 (enExample) | ||
| JP2018536648A5 (enExample) | ||
| JP2022542937A5 (enExample) | ||
| JP2024521895A5 (enExample) | ||
| JP2020527173A5 (enExample) | ||
| JP2022550353A5 (enExample) | ||
| JP2025503970A5 (enExample) |